WEREWOLF THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- WEREWOLF THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
- WEREWOLF THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-03-31 was 1.43M shares, a 53.99% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 936.00K shares, a 128.85% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month |
|---|---|---|---|
| 2026-06-30 | 0.00 shares S-4 · filed 2026-09-22 | 0.00 shares S-4 · filed 2026-09-22 | |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | ||
| 2023-03-31 | 1.43M shares 10-Q · filed 2023-05-11 | ||
| 2022-09-30 | 936.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 1.25M shares derived: sum of 2 quarters · filed 2022-11-10 | 2.18M shares 10-Q · filed 2022-11-10 |
| 2022-06-30 | 319.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 1.25M shares 10-Q · filed 2022-08-11 | |
| 2022-03-31 | 928.00K shares 10-Q · filed 2022-05-10 | ||
| 2021-09-30 | 409.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 960.00K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.32M shares 10-Q · filed 2021-11-10 |
| 2021-06-30 | 551.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 907.00K shares 10-Q · filed 2021-08-12 | |
| 2021-03-31 | 356.00K shares 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |